Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib intratumoral concentration and activity in cutaneous schwannomas
2011-001789-16Phase 4Completed
- Sponsor
- University Hospitals Plymouth
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sorafenib in neurofibromatosis type 2 (NF2) and schwannoma, sponsored by University Hospitals Plymouth. Primary endpoints: Target inhibition by sorafenib in cutaneous schwannoma biopsies, Steady-state plasma concentration of sorafenib and 2 more. Started May 2011; status: completed.
02
Drugs
sorafenib
03
Conditions
neurofibromatosis type 2 (NF2)schwannoma
Beyond the preview
Go deeper on 2011-001789-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001789-16.